AIDRANA 3 MG/0.02 MG FILM-COATED TABLETS

Introduction

Package Leaflet: Information for the User

aidrana 3 mg/ 0.02 mg film-coated tablets EFG

drospirenone/ethinylestradiol

Read this package leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this package leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.

• This medicine has been prescribed for you only, do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you experience any side effects, consult your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. See section 4.

Important things to know about combined hormonal contraceptives (CHCs):

• They are one of the most reliable reversible contraceptive methods if used correctly.
• They slightly increase the risk of having a blood clot in the veins and arteries, especially in the first year or when restarting a combined hormonal contraceptive after a break of 4 weeks or more.
• Be alert and consult your doctor if you think you might have symptoms of a blood clot (see section 2 “Blood clots”).

Package Leaflet Contents

1. What is aidrana and what it is used for
2. What you need to know before you start taking aidrana
3. How to take aidrana
4. Possible side effects
   1. Storage of aidrana

1. Contents of the pack and further information

1. What is aidrana and what it is used for

• aidrana is a contraceptive used to prevent pregnancy.
• Each of the 24 pink tablets contains a small amount of two different female hormones, called drospirenone and ethinylestradiol.
• The 4 white tablets do not contain active ingredients and are also called placebo tablets.

Contraceptives that contain two hormones are called combined contraceptives.

2. What you need to know before starting to take aidrana

When not to useaidrana

You should not use aidrana if you have any of the conditions listed below. Inform your doctor if you have any of the conditions listed below. Your doctor will discuss with you what other form of contraception would be more suitable.

Do not take aidrana:

• If you have (or have ever had) a blood clot in a blood vessel of the legs (deep vein thrombosis, DVT), in the lungs (pulmonary embolism, PE) or in other organs.
• If you know you have a disorder that affects blood clotting: for example, protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden or antiphospholipid antibodies.
• If you need an operation or if you spend a lot of time without getting up (see section "Blood clots").
• If you have ever had a heart attack or a stroke.
• If you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be the first sign of a heart attack) or a transient ischemic attack (TIA, temporary stroke symptoms).
• If you have any of the following diseases that may increase your risk of forming a clot in the arteries:

• Severe diabetes with blood vessel damage.
• Very high blood pressure.
• Very high levels of fat in the blood (cholesterol or triglycerides).
• A condition called hyperhomocysteinemia.

• If you have (or have ever had) a type of migraine called "migraine with aura".
• If you have (or have had in the past) a liver disease and your liver function has not yet normalized.
• If your kidneys do not work well (renal insufficiency).
• If you have (or have had in the past) a liver tumor.
• If you have (or have had in the past), or are suspected of having breast cancer or cancer of the sex organs.
• If you have vaginal bleeding, whose cause is unknown.
• If you are allergic to drospirenone or ethinylestradiol or to any of the other components of this medicine (included in section 6). This may manifest with itching, rash or inflammation.
• If you have hepatitis C and are taking medications that contain ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see also the section "Taking aidrana with other medicines").

Warnings and precautions

Tell your doctor if you suffer from any of the following conditions.

In some situations, you will need to be especially careful while using drospirenone/ethinylestradiol or any other combined hormonal contraceptive, and it may be necessary for your doctor to examine you periodically. If the condition develops or worsens while you are using drospirenone/ethinylestradiol, you should also inform your doctor

• If a close relative has or has had breast cancer.
• If you have any liver or gallbladder disease.
• If you have diabetes.
• If you have depression.
• If you have Crohn's disease or ulcerative colitis (chronic inflammatory bowel disease).
• If you have systemic lupus erythematosus (SLE, a disease that affects your natural defense system).
• If you have hemolytic uremic syndrome (HUS, a blood clotting disorder that causes kidney failure).
• If you have sickle cell anemia (a hereditary disease of red blood cells).
• If you have high levels of fat in the blood (hypertriglyceridemia) or a known family history of this condition. Hypertriglyceridemia has been associated with an increased risk of pancreatitis (inflammation of the pancreas).
• If you need an operation or spend a lot of time without getting up (see section 2 "Blood clots").
• If you have just given birth, you are at a higher risk of blood clots. You should ask your doctor when you can start taking aidrana after childbirth.
• If you have inflammation of the veins that are under the skin (superficial thrombophlebitis). If you have varicose veins.
• If you have epilepsy (see "Taking aidrana with other medicines").
• If you have some diseases that appeared for the first time during pregnancy or in a previous use of sex hormones (e.g., hearing loss, a blood disease called porphyria, blistering skin rash during pregnancy (gestational herpes), a nervous disease in which involuntary movements appear (Sydenham's chorea)). If you have or have had brownish spots (chloasma), also called "pregnancy spots", especially on the face. In this case, avoid direct exposure to the sun or ultraviolet rays.
• If you experience symptoms of angioedema such as swelling of the face, tongue and/or throat, and/or difficulty swallowing or urticaria, with possible difficulty breathing, contact a doctor immediately. Products containing estrogens can cause or worsen the symptoms of hereditary and acquired angioedema.

Consult your doctor or pharmacist before starting to take aidrana.

Psychiatric disorders:

Some women who use hormonal contraceptives like aidrana have reported depression or a depressed mood. Depression can be severe and sometimes can induce suicidal thoughts. If you experience mood changes and depressive symptoms, contact your doctor for additional medical advice as soon as possible.

BLOOD CLOTS

The use of a combined hormonal contraceptive like aidrana increases your risk of having a blood clotcompared to not using it. In rare cases, a blood clot can block blood vessels and cause serious problems.

Blood clots can form:

• In the veins (this is called "venous thrombosis", "venous thromboembolism" or VTE).
• In the arteries (this is called "arterial thrombosis", "arterial thromboembolism" or ATE).

Recovery from blood clots is not always complete. In rare cases, there can be serious long-term effects or, very rarely, they can be fatal.

It is essential to remember that the overall risk of a harmful blood clot due to aidrana is small.

HOW TO RECOGNIZE A BLOOD CLOT

Seek urgent medical attention if you notice any of the following signs or symptoms.

BLOOD CLOTS IN A VEIN

What can happen if a blood clot forms in a vein?

• The use of combined hormonal contraceptives has been associated with an increased risk of blood clots in the veins (venous thrombosis). However, these side effects are rare. They occur more frequently in the first year of use of a combined hormonal contraceptive.
• If a blood clot forms in a vein in the leg or foot, it can cause deep vein thrombosis (DVT).
• If a blood clot moves from the leg and lodges in the lung, it can cause a pulmonary embolism.
• In very rare cases, a clot can form in a vein of another organ such as the eye (retinal vein thrombosis)

When is the risk of a blood clot in a vein higher?

The risk of having a blood clot in a vein is higher during the first year in which you take a combined hormonal contraceptive for the first time. The risk may also be higher if you start taking a combined hormonal contraceptive (the same medicine or a different one) after an interruption of 4 weeks or more.

After the first year, the risk decreases, but it is always slightly higher than if you were not taking a combined hormonal contraceptive.

When you stop taking aidrana, your risk of having a blood clot returns to normal within a few weeks.

What is the risk of having a blood clot?

The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.

The overall risk of having a blood clot in the leg or lung (DVT or PE) with aidrana is small.

• Of every 10,000 women who do not use a combined hormonal contraceptive and are not pregnant, about 2 will have a blood clot in a year.
• Of every 10,000 women who use a combined hormonal contraceptive that contains levonorgestrel, norethisterone or norgestimate, about 5-7 will have a blood clot in a year.
• Of every 10,000 women who use a combined hormonal contraceptive that contains drospirenone such as drospirenone/ethinylestradiol, about 9-12 will have a blood clot in a year.
• The risk of having a blood clot will depend on your personal history (see "Factors that increase your risk of a blood clot" below).

Factors that increase your risk of a blood clot in a vein

The risk of having a blood clot with aidrana is small, but some conditions increase the risk. Your risk is higher:

• If you are overweight (body mass index or BMI over 30 kg/m2).
• If any of your close relatives have had a blood clot in the leg, lung or other organ at a young age (i.e., before the age of about 50). In this case, you may have a hereditary disorder of blood clotting.
• If you need to have an operation or if you spend a lot of time without getting up due to an injury or illness or if you have a leg in a cast. You may need to stop using aidrana several weeks before surgery or while you have less mobility. If you need to stop using aidrana, ask your doctor when you can start using it again.
• As you get older (especially above about 35 years).
• If you have recently given birth.

The risk of having a blood clot increases the more conditions you have.

Long-distance flights (more than 4 hours) may temporarily increase the risk of a blood clot, especially if you have any of the other risk factors listed.

It is essential to inform your doctor if you suffer from any of the above conditions, even if you are not sure. Your doctor may decide that you should stop using aidrana.

If any of the above conditions change while you are using aidrana, for example, a close relative experiences a thrombosis without a known cause or you gain much weight, inform your doctor.

BLOOD CLOTS IN AN ARTERY

What can happen if a blood clot forms in an artery?

Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.

Factors that increase your risk of a blood clot in an artery

It is essential to note that the risk of a heart attack or stroke due to drospirenone/ethinylestradiol is very small, but it can increase:

• With age (above about 35 years).
• If you smoke.When using a combined hormonal contraceptive like aidrana, you are advised to stop smoking. If you are unable to stop smoking and are over 35 years old, your doctor may advise you to use a different type of contraceptive.
• If you are overweight.
• If you have high blood pressure.
• If any of your close relatives have had a heart attack or stroke at a young age (less than about 50 years). In this case, you may also be at higher risk of having a heart attack or stroke.
• If you or any of your close relatives have a high level of fat in the blood (cholesterol or triglycerides).
• If you have migraines, especially migraines with aura.
• If you have a heart problem (valve disorder, heart rhythm disorder called atrial fibrillation).
• If you have diabetes.

If you have more than one of these conditions or if any of them are particularly severe, the risk of having a blood clot may be increased further.

If any of the above conditions change while you are using aidrana, for example, you start smoking, a close relative experiences a thrombosis without a known cause or you gain much weight, inform your doctor.

Drospirenone/ethinylestradiol andcancer

There has been a slightly higher incidence of breast cancer in women who use combined contraceptives, but it is not known if this is due to the treatment. For example, it may be that more tumors are detected in women who use combined contraceptives because they are examined by a doctor more frequently. The incidence of breast tumors decreases gradually after stopping combined hormonal contraceptives. It is essential to have your breasts examined regularly, and you should see your doctor if you notice any lump.

In rare cases, benign liver tumors, and more rarely malignant liver tumors, have been reported in users of hormonal contraceptives. See your doctor if you suffer from unusually severe abdominal pain.

Bleeding between periods

During the first few months in which you are taking aidrana, you may have unexpected bleeding (bleeding outside of the days of placebo pill use). If this bleeding persists beyond a few months or starts after a few months, your doctor should investigate the cause.

What should you do

3. How to take aidrana

Each blister pack contains 24 active pink tablets and 4 white placebo tablets. The aidrana tablets of different colors are ordered. A blister pack contains 28 tablets.

Take one aidrana tablet every day, with some water if necessary. You can take the tablets with or without food, but always at approximately the same time every day.

Do not confuse the tablets: take a pink tablet for the first 24 days and then a white tablet for the last 4 days. Then, start a new blister pack immediately (24 pink tablets and then 4 white tablets). Therefore, there is no interval between two blister packs.

Since the composition of the tablets is different, you must start the blister pack with the tablet in the upper left corner and take the tablets every day. Follow the direction of the arrows on the blister pack to take the tablets in the correct order.

Preparing the blister pack

To help you follow the order of intake, each aidrana package contains 7 self-adhesive strips with the 7 days of the week. Choose the strip that starts with the day you take the first tablet. For example, if you take your first tablet on a Wednesday, use the strip that starts with "WED".

Stick the self-adhesive strip on the top of the aidrana blister pack, where it says "Place the strip here!", so that the first day is above the tablet marked with "1".

Now you will have a day marked above each tablet and can visually check if you have taken your tablet. The arrows indicate the order of taking the tablets.

During the 4 days when you take the placebo tablets (the placebo days), you should have your period (the so-called withdrawal bleeding). It usually starts on the 2nd or 3rd day after taking the last active pink tablet of aidrana. After taking the last white tablet, start the next blister pack, even if your period has not finished. This means you must start the next blister pack on the same day of the week you started the previous one, and the withdrawal bleeding should occur during the same days every month.

If you use aidrana in this way, you are also protected against pregnancy during the 4 days when you take the placebo tablet.

When can you start with the first blister pack

• If you have not used any hormonal contraceptive in the previous month

Start taking aidrana on the first day of your cycle (i.e., the first day of your period). If you start aidrana on the first day of your period, you are immediately protected against pregnancy. You can also start on days 2-5 of your cycle, but in that case, you must use additional contraceptive methods (e.g., condoms) for the first 7 days.

• Switching from a combined hormonal contraceptive, vaginal ring, or patch

You can start taking aidrana preferably the day after taking the last active tablet (the last tablet containing active ingredients) of your previous contraceptive, but no later than the day after the tablet-free days (or after the last inactive tablet) of your previous contraceptive. When switching from a combined vaginal ring or patch, follow your doctor's recommendations.

• Switching from a progestin-only method (progestin-only pill, injection, implant, or intrauterine system)

You can switch from the progestin-only pill at any time. If it's an implant or intrauterine system, on the day of its removal; if it's an injectable, when the next injection is due. In all cases, it is recommended that you use additional contraceptive measures (e.g., condoms) for the first 7 days of tablet-taking.

• After an abortion

Follow your doctor's recommendations.

• After having a child

After having a child, you can start taking aidrana between 21 and 28 days later. If you start later, you must use a barrier method (e.g., condoms) for the first 7 days of aidrana use.

If, after having a child, you have already had sexual intercourse, before starting aidrana, you must be sure you are not pregnant or wait for your next period.

• If you are breastfeeding and want to start taking drospirenone/ethinylestradiol

Read the section "Lactation".

Consult your doctor if you have doubts about when to start.

If you take moreaidranathan you should

No cases have been reported where an overdose of aidrana has caused serious harm.

If you take many tablets at once, you may feel unwell or have vomiting or vaginal bleeding.

This bleeding can occur even in girls who have not yet had their first period, if they have accidentally taken this medication.

If you have taken too many aidrana tablets, or if a child has taken them, consult your doctor or pharmacist.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.

If you forget to takeaidrana

The last 4 tablets of the 4th row of the blister pack are placebo tablets. If you forget one of these tablets, the contraceptive effect of aidrana is not lost. You must discard the forgotten placebo tablet.

If you forget an active pink tablet (tablets 1-24 of the blister pack), follow these tips:

• If you are less than 24 hourslate in taking a tablet, the protection against pregnancy does not decrease. Take the tablet as soon as you remember and the following tablets at the usual time.

• If you are more than 24 hourslate in taking a tablet, the protection against pregnancy may be reduced. The more tablets you have forgotten, the higher the risk of becoming pregnant.

The risk of incomplete protection against pregnancy is highest if you forget a pink tablet at the beginning or end of the blister pack. The following recommendations should be followed in this situation (see also the diagram below):

• Forgetfulness of more than one tablet in the blister pack

Consult your doctor.

• Forgetfulness of a tablet duringdays 1-7 (first row)

Take the forgotten tablet as soon as you remember, even if it means taking two tablets at once. Continue taking the following tablets at the usual time and use additional precautions, for example, condoms, for the next 7 days. If you have had sexual intercourse in the week before forgetting the tablet, you should know that there is a risk of pregnancy. In that case, consult your doctor.

• Forgetfulness of a tablet during days 8-14 (second row)

Take the forgotten tablet as soon as you remember, even if it means taking two tablets at once. Continue taking the following tablets at the usual time. The protection against pregnancy does not decrease, and you do not need to take additional precautions.

• Forgetfulness of a tablet between days 15 and 24 (third or fourth row)

You can choose between two options:

1. Take the forgotten tablet as soon as you remember, even if it means taking two tablets at once. Continue taking the following tablets at the usual time. Instead of continuing with the white placebo tablets, discard them and start a new blister pack (the day you take the first tablet will be different).

You will likely have your period at the end of the second blister pack – during the intake of the white placebo tablets – although you may experience spotting or bleeding similar to menstruation during the intake of the second blister pack.

1. You can also stop taking the active pink tablets and go directly to the 4 white placebo tablets (before taking the placebo tablets, note the day you forgot to take your tablet). If you want to start a new blister pack on your fixed start day, take the placebo tablets for less than 4 days.

If you follow one of these two recommendations, you will remain protected against pregnancy.

If you have forgotten to take a tablet from a blister pack and do not have your period during the placebo days, this may mean that you are pregnant. In this case, you must see your doctor before continuing with the next blister pack.

What to do in case of vomiting or severe diarrhea

If you vomit within 3-4 hours after taking an active pink tablet or if you have severe diarrhea, there is a risk that the active ingredients of the tablet will not be fully absorbed by your body. This is similar to what happens when you forget a tablet. After vomiting or diarrhea, you must take a pink tablet from a reserve package as soon as possible. If possible, take it within 24 hours after the usual time you take your contraceptive. If it is not possible or more than 24 hours have passed, follow the tips in the section "If you forget to take aidrana".

Delayed menstrual period: what you should know

Although it is not recommended, it is possible to delay your menstrual period if you do not take the white placebo tablets from the 4th row and start directly taking the tablets from a new aidrana blister pack until you finish this new blister pack. You may experience spotting (drops or spots of blood) or bleeding similar to menstruation during the use of the second blister pack. After finishing this second blister pack, taking the 4 white tablets from the 4th row, you start the next blister pack.

Before deciding to delay your menstrual period, ask your doctor.

Changing the first day of your menstrual period: what you should know

If you take the tablets according to the instructions, your menstrual period will begin during the placebo days. If you need to change this day, you can do so by reducing the placebo days (the days you take the white tablets) but never extending them – 4 days is the maximum! For example, if you start the placebo days on a Friday and want to change it to Tuesday (3 days earlier), you must start a new blister pack 3 days earlier than usual. You may not have bleeding during these placebo days. Then you may experience spotting or bleeding similar to menstruation.

If you are not sure how to proceed, consult your doctor.

If you interrupt treatment withaidrana

You can stop taking aidrana at any time. If you do not want to become pregnant, consult your doctor about other effective birth control methods. If you want to become pregnant, stop taking aidrana and wait until your next period before trying to become pregnant. This way, you can more easily calculate the estimated date of delivery.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

If you experience any adverse effect, especially if it is severe and persistent, or if you have any change in health that you think may be due to aidrana, consult your doctor.

Contact a doctor immediately if you experience any of the following symptoms of angioedema: swelling of the face, tongue and/or throat, and/or difficulty swallowing or urticaria with possible difficulty breathing (see also section "Warnings and Precautions").

All women who take combined hormonal contraceptives are at a higher risk of developing blood clots in the veins (venous thromboembolism (VTE)) or blood clots in the arteries (arterial thromboembolism (ATE)). For more detailed information on the different risks of taking combined hormonal contraceptives, see section 2 "What you need to know before taking aidrana".

The following adverse effects are related to the use of aidrana:

Frequent Adverse Effects: may affect up to 1 in 10 people

• mood changes
• headache
• nausea
• breast pain, menstrual problems such as irregular periods, absence of periods

Uncommon Adverse Effects: may affect up to 1 in 100 people

• depression, nervousness, drowsiness
• dizziness, tingling and numbness
• migraine, varicose veins, increased blood pressure
• stomach pain, vomiting, indigestion, intestinal gas, stomach inflammation, diarrhea
• acne, itching, skin rash
• discomfort and pain, such as back pain, pain in the limbs, muscle cramps
• vaginal yeast infection, pain in the lower abdominal region (pelvic), breast enlargement, benign breast lumps, uterine/vaginal bleeding (which usually subsides during treatment), vaginal discharge, hot flashes, vaginal inflammation (vaginitis), menstrual problems, painful periods, shorter periods, heavy periods, vaginal dryness, abnormal cervical smear, loss of interest in sex
• lack of energy, increased sweating, fluid retention
• weight gain

Rare Adverse Effects: may affect up to 1 in 1,000 people

• candidiasis (a fungal infection)
• anemia, increased platelet count in the blood
• allergic reaction
• hormonal disorder (endocrine)
• increased appetite, loss of appetite, abnormally high potassium levels in the blood, abnormally low sodium levels in the blood
• absence of orgasm, insomnia
• vertigo, tremors
• eye disorders, such as eyelid inflammation, dry eyes
• abnormally rapid heart rate
• vein inflammation, nosebleeds, fainting
• abdominal enlargement, intestinal disorder, feeling of bloating, gastric hernia, oral thrush, constipation, dry mouth
• pain in the bile ducts or gallbladder, gallbladder inflammation
• brownish-yellow spots on the skin, eczema, hair loss, acne-like skin inflammation, dry skin, skin inflammation with swelling, excessive hair growth, skin disorders, stretch marks on the skin, skin inflammation, skin inflammation due to photosensitivity, skin nodules
• difficult or painful sex, vaginal inflammation (vulvovaginitis), bleeding after sex, withdrawal bleeding, breast cysts, increased number of breast cells (hyperplasia), malignant breast lumps, abnormal growth of the mucous membrane of the cervix, shrinkage or loss of uterine lining, fluid-filled sacs in an ovary, uterine enlargement
• discomfort
• weight loss
• harmful blood clots in a vein or artery, for example:

• In a leg or foot (i.e., DVT).
• In a lung (i.e., PE).
• Heart attack.
• Stroke.
• Mild stroke or temporary symptoms similar to those of a stroke, called a transient ischemic attack (TIA).
• Blood clots in the liver, stomach/intestine, kidneys, or eye

The chances of having a blood clot may be higher if you have any other condition that increases this risk (see section 2 for more information on conditions that increase the risk of blood clots and symptoms of a blood clot).

The following adverse effects have also been reported, but their frequency cannot be estimated from the available data: hypersensitivity, erythema multiforme (skin rash with target-like redness or ulcers).

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of aidrana

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date that appears on the packaging after "EXP". The expiration date is the last day of the month indicated.

Do not store above 30 °C.

Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.

6. Package Contents and Additional Information

Composition of aidrana

• The active ingredients are drospirenone and ethinylestradiol.

Each active film-coated pink tablet contains 3 milligrams of drospirenone and 0.02 milligrams of ethinylestradiol.

The white film-coated tablets do not contain active ingredients.

• The other components are:

Active film-coated pink tablets

Tablet core:lactose monohydrate, potassium polacrylate, povidone K-30, magnesium stearate.

Tablet film coating:macrogol 3350, titanium dioxide (E171), polyvinyl alcohol, talc, red iron oxide (E172), and yellow iron oxide (E172).

Inactive white film-coated tablets:

Tablet core:lactose monohydrate, potassium polacrylate, povidone K-30, magnesium stearate, anhydrous colloidal silica

Tablet film coating:macrogol 3350, titanium dioxide (E171), polyvinyl alcohol, talc.

Appearance of the Product and Package Contents

• Each aidrana blister pack contains 24 active film-coated pink tablets in the 1st, 2nd, 3rd, and 4th row of the blister pack, and 4 white film-coated placebo tablets in the 4th row.

• Aidrana tablets, both pink and white, are film-coated tablets; the tablet core is coated.

• The active tablet is cylindrical with a diameter of approximately 6 mm, biconvex, and pink in color.

• The placebo tablet is cylindrical with a diameter of approximately 6 mm, biconvex, and white in color.

Aidrana is available in packages of 1 and 3 blister packs, each containing 28 tablets.

Only some package sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) - Spain

Manufacturer

Cyndea Pharma, S.L.

Polígono Industrial Emiliano Revilla

Av. De Ágreda 31

42110 Ólvega (Soria)- Spain

or

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) - Spain

Date of the Last Revision of this Prospectus:July 2024

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es

You can access detailed and updated information about this medicine by scanning the QR code included in the prospectus and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/83761/P_83761.html

QR code to: https://cima.aemps.es/cima/dochtml/p/83761/P_83761.html